Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARE Alexandria Real Estate Equities	$81.84 +0.1%	$77.18	$67.37 ▼ $125.63	$14.13B	1.24	1.52 million shs	793,509 shs
BXP BXP	$71.72 +0.9%	$68.17	$54.22 ▼ $90.11	$11.25B	1.17	1.69 million shs	1.30 million shs
KRC Kilroy Realty	$41.76 +1.5%	$37.16	$27.07 ▼ $43.78	$4.87B	1.22	1.37 million shs	1.42 million shs
MRNA Moderna	$24.47 -2.5%	$29.12	$23.15 ▼ $79.96	$9.77B	1.83	9.63 million shs	10.56 million shs

Beginner's Guide To Retirement Stocks

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARE Alexandria Real Estate Equities	+0.07%	+5.80%	+2.89%	+16.73%	-31.29%
BXP BXP	+0.86%	+8.09%	+1.77%	+6.64%	-3.48%
KRC Kilroy Realty	+1.41%	+7.52%	+9.18%	+29.62%	+15.72%
MRNA Moderna	-2.51%	-6.67%	-25.08%	-7.87%	-68.77%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ARE Alexandria Real Estate Equities	4.5319 of 5 stars	2.1	5.0	4.2	2.2	3.6	1.7	1.3
BXP BXP	3.0695 of 5 stars	2.2	1.0	2.5	1.8	2.3	1.7	0.6
KRC Kilroy Realty	4.0457 of 5 stars	2.0	1.0	2.5	2.7	3.5	2.5	1.9
MRNA Moderna	4.4944 of 5 stars	4.0	2.0	0.0	4.6	2.7	2.5	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ARE Alexandria Real Estate Equities	2.18	Hold	$97.17	18.73% Upside
BXP BXP	2.40	Hold	$76.73	7.00% Upside
KRC Kilroy Realty	2.00	Hold	$38.55	-7.70% Downside
MRNA Moderna	2.04	Hold	$42.88	75.24% Upside

Current Analyst Ratings Breakdown

Latest ARE, MRNA, BXP, and KRC Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/28/2025	KRC Kilroy Realty	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Underperform ➝ Underperform
8/28/2025	BXP BXP	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Sector Perform ➝ Sector Perform	$81.00 ➝ $77.00
8/28/2025	KRC Kilroy Realty	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Sector Underperform ➝ Sector Underperform	$37.00 ➝ $40.00
8/27/2025	BXP BXP	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$78.00 ➝ $77.00
8/27/2025	KRC Kilroy Realty	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Equal Weight ➝ Equal Weight	$33.00 ➝ $40.00
8/22/2025	MRNA Moderna	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Underperform ➝ Underperform	$18.00 ➝ $15.00
8/21/2025	KRC Kilroy Realty	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Sell	$33.00
8/18/2025	KRC Kilroy Realty	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	In-Line ➝ In-Line	$43.00 ➝ $42.00
8/14/2025	BXP BXP	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$76.00 ➝ $68.00
8/8/2025	KRC Kilroy Realty	Zacks Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold
8/7/2025	KRC Kilroy Realty	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Sector Perform ➝ Sector Perform	$39.00 ➝ $40.00

(Data available from 8/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ARE Alexandria Real Estate Equities	$3.12B	4.54	$8.44 per share	9.70	$125.63 per share	0.65
BXP BXP	$3.41B	3.33	$7.72 per share	9.29	$49.55 per share	1.45
KRC Kilroy Realty	$1.14B	4.35	$4.91 per share	8.51	$47.28 per share	0.88
MRNA Moderna	$3.06B	3.12	N/A	N/A	$24.16 per share	1.01

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ARE Alexandria Real Estate Equities	$322.95M	-$0.13	N/A	8.51	6.87	-0.33%	-0.05%	-0.03%	10/27/2025 (Estimated)
BXP BXP	$14.27M	$0.03	2,391.30	9.86	3.93	0.11%	3.89%	1.20%	11/4/2025 (Estimated)
KRC Kilroy Realty	$210.97M	$1.84	22.70	10.06	N/A	19.29%	3.92%	1.99%	10/27/2025 (Estimated)
MRNA Moderna	-$3.56B	-$7.53	N/A	N/A	N/A	-94.31%	-25.96%	-20.09%	11/6/2025 (Estimated)

Latest ARE, MRNA, BXP, and KRC Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/1/2025	Q2 2025	MRNA Moderna	-$2.99	-$2.13	+$0.86	-$2.13	$116.26 million	$142.00 million
7/29/2025	Q2 2025	BXP BXP	$1.67	$1.71	+$0.04	$1.71	$845.09 million	$868.46 million
7/28/2025	Q2 2025	KRC Kilroy Realty	$1.01	$1.13	+$0.12	$1.13	$268.84 million	$289.89 million
7/21/2025	Q2 2025	ARE Alexandria Real Estate Equities	$2.29	$2.33	+$0.04	$2.33	$748.02 million	$737.28 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ARE Alexandria Real Estate Equities	$5.28	6.45%	N/A	N/A	15 Years
BXP BXP	$3.92	5.47%	N/A	13,066.67%	N/A
KRC Kilroy Realty	$2.16	5.17%	N/A	117.39%	N/A
MRNA Moderna	N/A	N/A	N/A	N/A	N/A

Latest ARE, MRNA, BXP, and KRC Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
6/20/2025	BXP BXP	quarterly	$0.98	5.47%	6/30/2025	6/30/2025	7/31/2025
6/2/2025	ARE Alexandria Real Estate Equities	quarterly	$1.32	7.64%	6/30/2025	6/30/2025	7/15/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ARE Alexandria Real Estate Equities	0.61	0.23	0.23
BXP BXP	2.06	3.76	3.76
KRC Kilroy Realty	0.82	2.35	2.35
MRNA Moderna	N/A	3.93	3.77

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ARE Alexandria Real Estate Equities	96.54%
BXP BXP	98.72%
KRC Kilroy Realty	94.22%
MRNA Moderna	75.33%

Insider Ownership

Company	Insider Ownership
ARE Alexandria Real Estate Equities	1.08%
BXP BXP	1.49%
KRC Kilroy Realty	1.57%
MRNA Moderna	11.00%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ARE Alexandria Real Estate Equities	590	172.96 million	171.09 million	Optionable
BXP BXP	780	158.38 million	156.02 million	Optionable
KRC Kilroy Realty	260	118.29 million	116.44 million	Optionable
MRNA Moderna	5,800	389.08 million	346.28 million	Optionable

ARE, MRNA, BXP, and KRC Headlines

Recent News About These Companies

FDA approves mRNA vaccines for new Covid-19 season amid political tension

August 28 at 8:47 PM | finance.yahoo.com

FDA Approves Updated COVID-19 Vaccines but With Restrictions

August 28 at 1:06 PM | zacks.com

Aristides Capital LLC Purchases Shares of 20,000 Moderna, Inc. $MRNA

August 28 at 8:19 AM | marketbeat.com

Moderna, Inc. (MRNA) Expands Into Oncology with Pan-Tumor Vaccine

August 28 at 6:31 AM | insidermonkey.com

Moderna Receives U.S. FDA Approval for Updated COVID-19 Vaccines Targeting LP.8.1 Variant of SARS-CoV-2

August 27 at 1:24 PM | accessnewswire.comA

Moderna (NASDAQ:MRNA) Stock Price Down 5.2% Following Analyst Downgrade

August 27 at 12:09 PM | marketbeat.com

Moderna, Inc. $MRNA Shares Sold by Groupe la Francaise

August 27 at 5:57 AM | marketbeat.com

“GPS” Molecules Help Maximize the Effectiveness of mRNA Vaccines

August 27 at 5:47 AM | technologynetworks.comT

Moderna, Inc. $MRNA Shares Bought by Northern Trust Corp

August 27 at 4:02 AM | marketbeat.com

Moderna (NASDAQ:MRNA) Stock Price Down 5.2% on Analyst Downgrade

August 27 at 2:17 AM | americanbankingnews.com

Moderna, Inc. $MRNA Shares Sold by Hsbc Holdings PLC

August 26 at 4:23 AM | marketbeat.com

Cresset Asset Management LLC Invests $522,000 in Moderna, Inc. $MRNA

August 26 at 3:51 AM | marketbeat.com

Option traders moderately bearish in Moderna with shares down 5.33%

August 26 at 3:31 AM | msn.com

How Moderna went from saving society to a shrinking share price

August 25, 2025 | theglobeandmail.com

Landmark Cancer Vaccines Face Delays Due to Robert F. Kennedy Jr.’s mRNA Cuts

August 25, 2025 | usnews.com

Jump Financial LLC Purchases 886,567 Shares of Moderna, Inc. $MRNA

August 25, 2025 | marketbeat.com

Health Canada approves Moderna’s updated Covid-19 mRNA vaccine, Spikevax, targeting SARS-CoV-2 variant LP.8.1

August 25, 2025 | pharmabiz.comP

Moderna’s updated Covid-19 vaccine gets Canadian approval

August 25, 2025 | finance.yahoo.com

Wellington Management Group LLP Reduces Stock Position in Moderna, Inc. $MRNA

August 25, 2025 | marketbeat.com

Moderna, Inc. $MRNA Shares Purchased by Korea Investment CORP

August 25, 2025 | marketbeat.com

Russell Investments Group Ltd. Sells 10,580 Shares of Moderna, Inc. $MRNA

August 25, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

ARE, MRNA, BXP, and KRC Company Descriptions

Alexandria Real Estate Equities NYSE:ARE

$81.84 +0.12 (+0.14%)

Closing price 08/28/2025 03:59 PM Eastern

Extended Trading

$81.50 -0.34 (-0.41%)

As of 05:29 AM Eastern

Alexandria Real Estate Equities, Inc. (NYSE: ARE), an S&P 500 company, is a best-in-class, mission-driven life science REIT making a positive and lasting impact on the world. As the pioneer of the life science real estate niche since our founding in 1994, Alexandria is the preeminent and longest-tenured owner, operator, and developer of collaborative life science, agtech, and advanced technology mega campuses in AAA innovation cluster locations, including Greater Boston, the San Francisco Bay Area, New York City, San Diego, Seattle, Maryland, and Research Triangle. Alexandria has a total market capitalization of $33.1 billion and an asset base in North America of 73.5 million SF as of December 31, 2023, which includes 42.0 million RSF of operating properties, 5.5 million RSF of Class A/A+ properties undergoing construction and one near-term project expected to commence construction in the next two years, 2.1 million RSF of priority anticipated development and redevelopment projects, and 23.9 million SF of future development projects. Alexandria has a longstanding and proven track record of developing Class A/A+ properties clustered in life science, agtech, and advanced technology mega campuses that provide our innovative tenants with highly dynamic and collaborative environments that enhance their ability to successfully recruit and retain world-class talent and inspire productivity, efficiency, creativity, and success. Alexandria also provides strategic capital to transformative life science, agrifoodtech, climate innovation, and technology companies through our venture capital platform. We believe our unique business model and diligent underwriting ensure a high-quality and diverse tenant base that results in higher occupancy levels, longer lease terms, higher rental income, higher returns, and greater long-term asset value.

BXP NYSE:BXP

$71.72 +0.67 (+0.94%)

Closing price 08/28/2025 03:59 PM Eastern

Extended Trading

$71.67 -0.05 (-0.06%)

As of 08/28/2025 06:18 PM Eastern

Boston Properties, Inc. (NYSE: BXP) (BXP or the Company) is the largest publicly traded developer, owner, and manager of premier workplaces in the United States, concentrated in six dynamic gateway markets - Boston, Los Angeles, New York, San Francisco, Seattle, and Washington, DC. BXP has delivered places that power progress for our clients and communities for more than 50 years. BXP is a fully integrated real estate company, organized as a real estate investment trust (REIT). Including properties owned by joint ventures, BXP's portfolio totals 53.3 million square feet and 188 properties, including 10 properties under construction/redevelopment. BXP's properties include 167 office properties, 14 retail properties (including two retail properties under construction/redevelopment), six residential properties (including one residential property under construction) and one hotel. BXP is well-known for its inhouse building management expertise and responsiveness to clients' needs. BXP holds a superior track record of developing premium Central Business District (CBD) office buildings, successful mixed-use complexes, suburban office centers and build-to-suit projects for a diverse array of creditworthy clients. BXP actively works to promote its growth and operations in a sustainable and responsible manner. BXP has earned a twelfth consecutive GRESB Green Star recognition and the highest GRESB 5-star Rating. BXP, an S&P 500 company, was founded in 1970 by Mortimer B. Zuckerman and Edward H. Linde and became a public company in 1997.

Kilroy Realty NYSE:KRC

$41.76 +0.61 (+1.49%)

Closing price 08/28/2025 03:59 PM Eastern

Extended Trading

$41.75 -0.01 (-0.03%)

As of 08/28/2025 06:06 PM Eastern

Kilroy Realty Corporation (NYSE: KRC, the company, Kilroy) is a leading U.S. landlord and developer, with operations in San Diego, Greater Los Angeles, the San Francisco Bay Area, Greater Seattle and Austin. The company has earned global recognition for sustainability, building operations, innovation and design. As a pioneer and innovator in the creation of a more sustainable real estate industry, the company's approach to modern business environments helps drive creativity and productivity for some of the world's leading technology, entertainment, life science and business services companies. The company is a publicly traded real estate investment trust (REIT) and member of the S&P MidCap 400 Index with more than seven decades of experience developing, acquiring and managing office, life science and mixed-use projects. As of December 31, 2023, Kilroy's stabilized portfolio totaled approximately 17.0 million square feet of primarily office and life science space that was 85.0% occupied and 86.4% leased. The company also had approximately 1,000 residential units in Hollywood and San Diego, which had a quarterly average occupancy of 92.5%. In addition, the company had two in-process life science redevelopment projects totaling approximately 100,000 square feet with total estimated redevelopment costs of $80.0 million and one approximately 875,000 square foot in-process development project with a total estimated investment of $1.0 billion.

Moderna NASDAQ:MRNA

$24.47 -0.63 (-2.51%)

Closing price 08/28/2025 04:00 PM Eastern

Extended Trading

$24.42 -0.05 (-0.20%)

As of 06:01 AM Eastern

Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; rare disease intracellular therapeutics; and inhaled pulmonary therapeutics. It has strategic alliances and collaborations with AstraZeneca; Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Chiesi Farmaceutici S.p.A.; Metagenomi, Inc.; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time